Your browser doesn't support javascript.
loading
IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis.
Ochsner, Scott A; Pedroza, Mesias; Pillich, Rudolf T; Krishnan, Venkatesh; Konicek, Bruce W; Dow, Ernst R; Park, So Young; Agarwal, Sandeep K; McKenna, Neil J.
Affiliation
  • Ochsner SA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Pedroza M; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Pillich RT; Department of Medicine, University of California San Diego, California, USA.
  • Krishnan V; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Konicek BW; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Dow ER; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Park SY; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Agarwal SK; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • McKenna NJ; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: nmckenna@bcm.edu.
J Invest Dermatol ; 143(9): 1689-1699, 2023 09.
Article in En | MEDLINE | ID: mdl-36967086
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: J Invest Dermatol Year: 2023 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: J Invest Dermatol Year: 2023 Document type: Article Affiliation country: United States